Table 1.
Basic parameters of patients, according to the initial data.
| Parameters | Colchicine (n = 50) |
Placebo (n = 51) |
p |
|---|---|---|---|
| Clinical parameters of patients | |||
| Age, y | 63 (56; 68) | 60 (55; 67) | 0.420 |
| Male, n (%) | 41 (82) | 41 (80,4) | 1.000 |
| BSA, m2 | 2.01 (1.9; 2.18) | 2.04 (1.87; 2.14) | 0.922 |
| Weight, kg | 85 (74; 94.3) | 87 (75; 95) | 0.984 |
| BMI, kg/m2 | 29.3 (26.6; 32.1) | 28.4 (24.7; 32.4) | 0.561 |
| Angina pectoris, n (%) | 47 (94) | 47 (92.2) | 1.000 |
| Angina pectoris class III-IV, n (%) | 30 (60) | 28 (54.9) | 0.604 |
| Diabetes, n (%) | 14 (28) | 9 (17.6) | 0.215 |
| COPD, n (%) | 2 (4) | 2 (3.9) | 1.000 |
| Hypertension, n (%) | 47 (94) | 48 (94.1) | 1.000 |
| Prior AMI, n (%) | 21 (42) | 24 (47.1) | 0.609 |
| Stroke, n (%) | 2 (4) | 1 (2) | 0.617 |
| Smoking, n (%) | 10 (20) | 14 (27.5) | 0.379 |
| Echocardiographic parameters | |||
| LVEF, % | 59.5 (56; 64) | 60 (55; 67) | 0.276 |
| LVESD/BSA, cm/m2 | 16.5 (15.7; 18.4) | 16 (14.6; 17.6) | 0.138 |
| LVEDD/BSA, cm/m2 | 24.8 (23.2; 26.7) | 23.6 (21.8; 26.1) | 0.135 |
| LVESV/BSA, mL/m2 | 22.8 (19.2; 28.6) | 20.4 (16.3; 26.1) | 0.058 |
| LVEDV/BSA, mL/m2 | 56.3 (48.8; 69.2) | 53.3 (44.2; 62.4) | 0.079 |
| AV peak gradient, mm Hg | 9 (7; 47.3) | 9.5 (5.2; 44.8) | 0.711 |
| AV mean gradient, mm H g | 5 (3.4; 31.5) | 10.5 (3.9; 55) | 0.171 |
| MR, degree | 1.5 (1; 2) | 1.5 (1; 1.5) | 0.483 |
| AR, degree | 1 (0; 1,5) | 1.5 (1; 1.5) | 0.122 |
| LV PWth, mm | 9 (9; 14.3) | 13 (11.5; 15) | 0.211 |
| IVS, mm | 13 (12; 15) | 13 (12; 14.3) | 0.935 |
| LA size, cm | 4.2 (3.8; 4.6) | 4.1 (3.7; 4.5) | 0.596 |
| Laboratory data | |||
| WBC, 109/L | 7.9 (6.8; 8.7) | 7.5 (6.6; 9.1) | 0.973 |
| Neutrophils, 109/L | 4.6 (3.8; 5.2) | 4.7 (3.5; 5.3) | 0.863 |
| Neutrophils, % | 60.7 (54; 65.1) | 58.8 (52.5; 63) | 0.532 |
| Platelets,109/L | 247.5 (191.7; 295) | 253 (205; 292) | 0.519 |
| Creatinine, mkmol/L | 85 (73; 94.3) | 80 (74; 95) | 0.732 |
| eGFR mL/min per 1.73 m2 (MDRD) | 93.5 (79.8; 107.3) | 90 (77; 109) | 0.954 |
| Glucose, mmol/L | 5.6 (5; 6.5) | 5.5 (5; 6.1) | 0.530 |
| AST, IU/L | 20.5 (17; 30.8) | 21 (17.8; 28.5) | 0.921 |
| ALT, IU/L | 23 (18; 33) | 27 (17.8; 34) | 0.444 |
| Potassium, mmol/L | 4.4 (4.1; 5) | 4.6 (4.2; 4.8) | 0.488 |
| Drug therapy | |||
| Beta-blockers, % | 41 (82) | 37 (72.5) | 0.257 |
| ACE inhibitors, % | 31 (62) | 29 (56.9) | 0.599 |
| Calcium antagonists, % | 17 (34) | 16 (31.4) | 0.778 |
| Thiazide diuretics,% | 8 (16) | 3 (5.9) | 0.122 |
| Loop diuretics, % | 7 (14) | 2 (3.9) | 0.092 |
| Potassium-sparing diuretics, % | 8 (16) | 8 (15.7) | 1.000 |
| NSAIDs, n (%) | 0 (0) | 0 (0) | |
| Acetylsalicylic acid, n (%) | 11 (22) | 8 (15.7) | 0.455 |
| Other antiaggregant, n (%) | 3 (6) | 3 (5.9) | 1.000 |
| Nitrates, % | 14 (28) | 12 (23.5) | 0.607 |
| Statins, % | 35 (70) | 35 (68.6) | 0.881 |
| LMWHs/UFH, n (%) | 14 (28) | 15 (29.4) | 0.875 |
BSA—body surface area, BMI—body mass index, COPD-chronic obstructive pulmonary disease, AMI—acute myocardial infarction, LV EF—left ventricular ejection fraction, LVEDD—left ventricular end diastolic diameter, LVEDV—left ventricular end diastolic volume, LVESD—left ventricular end systolic diameter, LVESV—left ventricular end systolic volume, AV—aortic valve, MR—mitral regurgitation, AR—aortic regurgitation, LV PWth—left ventricular posterior wall thickness, LA—eft atrium, WBC-white blood cells, eGFR—glomerular filtration rate, MDRD—Modification of diet in renal disease, AST—aspartate aminotransferase, ALT—alanine aminotransferase, ACE—angiotensin-converting enzyme, NSAIDs—nonsteroidal anti-inflammatory drugs, LMWHs—low-molecular-weight heparins.